Study of Arixtra to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
This study has been terminated.
(Problems with accrual)
Sponsor:
University of Alabama at Birmingham
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
Warner Huh, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00539942
First received: October 3, 2007
Last updated: February 7, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies. This trial seeks to determine if there is a difference in the rate of deep venous thrombosis between these two groups.
| Condition | Intervention | Phase |
|---|---|---|
|
Venous Thrombosis |
Drug: Fondaparinux sodium |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery With Intermittent Compression Devices (ICD) With or Without Postoperative Arixtra: A Randomized Controlled Trial |
Resource links provided by NLM:
Further study details as provided by University of Alabama at Birmingham:
Primary Outcome Measures:
- Comparison of Deep Venous Thromboembolism (DVT) Using Intermittent Compression Devices With and Without Arixtra [ Time Frame: 21 days ] [ Designated as safety issue: No ]Deep venous thromboembolism (DVT) rates are determined from lower extremity doppler ultrasound measurements.
Secondary Outcome Measures:
- Incidence of Untoward Effects With Arixtra [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]Adverse events will be evaluated to determine untoward effects.
| Enrollment: | 7 |
| Study Start Date: | April 2007 |
| Study Completion Date: | June 2010 |
| Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Intermittent compression devices (ICD)
All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
|
|
|
Experimental: Arixtra
Patients randomized to treatment arm will initiate Arixtra treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
|
Drug: Fondaparinux sodium
Treatment will consist of daily injections of pharmacy prepared syringes of fondaparinux sodium 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
Other Name: Arixtra
|
Detailed Description:
To assess the effectiveness of Arixtra in the prophylaxis of deep venous thromboembolism in gynecologic oncology patients undergoing abdominopelvic surgery.
Eligibility| Ages Eligible for Study: | 19 Years to 85 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- All patients undergoing open laparotomy (non-laparoscopic) gynecologic surgery.
- Patients must be competent to self-administer injections, or must have caregivers or nurses who can perform injections
- Patients must have signed an approved informed consent
Exclusion Criteria:
- Patients with medical history which requires chronic anticoagulation (i.e. previous DVT, pulmonary embolism, atrial fibrillation, heart valve replacement)
- Patients with contraindications to anticoagulation (generalized bleeding disorders, peptic ulcer disease, hemorrhagic stroke, etc)
- Contraindications to placement of ICDs (history of lower extremity venous stasis ulcers)
- Patients receiving low molecular weight heparin or unfractionated heparin for prophylaxis post-operatively
- Patients who are unable to receive injections as an outpatient and/or unable to undergo a doppler ultrasound of the lower extremities
- Renal insufficiency (creatinine clearance < 30 mL/min)
- Patients who have a body weight < 50 kg
- Hypersensitivity to low molecular weight heparin
- Patients who are pregnant or have a positive pregnancy test.
- Patients receiving continuous (indwelling) epidural.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00539942
Locations
| United States, Alabama | |
| UAB, Women's and Infant Center, 1700 6th Avenue South | |
| Birmingham, Alabama, United States, 35233 | |
Sponsors and Collaborators
University of Alabama at Birmingham
GlaxoSmithKline
Investigators
| Principal Investigator: | Warner K. Huh, M.D. | University of Alabama at Birmingham |
More Information
No publications provided
| Responsible Party: | Warner Huh, Principal Investigator, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT00539942 History of Changes |
| Other Study ID Numbers: | F070727009, UAB 0723 |
| Study First Received: | October 3, 2007 |
| Results First Received: | February 7, 2012 |
| Last Updated: | February 7, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Alabama at Birmingham:
|
Randomized Clinical Trials Randomized Controlled Trial Venous thrombosis |
Anticoagulant Drugs Doppler Ultrasound Postoperative complications |
Additional relevant MeSH terms:
|
Thrombosis Venous Thrombosis Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thromboembolism Fondaparinux PENTA |
Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 21, 2013